Ironwood Pharmaceuticals, Inc. (FRA:I76)
Germany · Delayed Price · Currency is EUR | Market Cap | 628.23M +258.0% |
| Revenue (ttm) | 340.77M +26.2% |
| Net Income | 113.67M |
| EPS | 0.69 |
| Shares Out | n/a |
| PE Ratio | 5.53 |
| Forward PE | 3.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.600 |
| Previous Close | 3.560 |
| Day's Range | 3.540 - 3.600 |
| 52-Week Range | 1.080 - 4.480 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C ... [Read more]
Financial Performance
In 2025, Ironwood Pharmaceuticals's revenue was $296.15 million, a decrease of -15.72% compared to the previous year's $351.41 million. Earnings were $24.02 million, an increase of 2629.20%.
Financial numbers in USD Financial StatementsNews
Ironwood Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted a turnaround year with strong revenue growth, improved cash flow, and successful debt reduction. LINZESS regained blockbuster status, and apraglutide's development is progressing with a new FDA-requested trial and a targeted NDA submission by 2029. Market access, pricing clarity, and a focused commercial strategy support continued growth.
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thurs...
Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2026
LINZESS achieved strong Q2 sales growth and raised full-year guidance, supported by robust demand and improved pricing. Apraglutide advanced with the initiation of the STARS-2 phase III trial, while financial results showed increased profitability and reduced debt.
Ironwood Pharmaceuticals Earnings release: Q2 2026
Ironwood Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ironwood Pharmaceuticals Slides: Q2 2026
Ironwood Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Ironwood Pharmaceuticals Quarterly report: Q2 2026
Ironwood Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Th...
Ironwood CMO Michael Shetzline to retire, Jeffrey Silber to succeed
Ironwood (IRWD) Pharmaceuticals announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his succe...
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Management projects a turnaround year with significant net sales growth, debt reduction, and strong LINZESS performance. Apraglutide advances with a new confirmatory trial and is positioned for class leadership due to its clinical profile and tolerability.
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, J...
Ironwood says FDA approves use of Linzess in pediatric patients two and older
Ironwood (IRWD) Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the use of Linzess in pediatric patients 2 years of age and older with functional constipation. “Linze...
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 97% year-over-year LINZESS net sales growth, strong profits, and progress on pediatric and rare disease indications. Apraglutide's clinical program advanced, with a large addressable market and robust safety data. Guidance for 2026 was reiterated.
Ironwood Pharmaceuticals Earnings release: Q1 2026
Ironwood Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ironwood Pharmaceuticals Slides: Q1 2026
Ironwood Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ironwood Pharmaceuticals Quarterly report: Q1 2026
Ironwood Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and ...
Ironwood presents new findings at DDW 2026 from survey treatment of SBS
Ironwood (IRWD) Pharmaceuticals presented new findings at Digestive Diseases Week, DDW, 2026 from a survey assessing healthcare provider, HCP, perspectives on the use of total parenteral nutrition, TP...
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thu...
Ironwood Pharmaceuticals Proxy statement: Proxy filing
Ironwood Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Ironwood Pharmaceuticals Proxy statement: Proxy filing
Ironwood Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Ironwood to present data from Landmark survey on SBS
Ironwood (IRWD) Pharmaceuticals announced that the company will present data from its Landmark survey during the 2026 Digestive Disease Week, DDW, meeting being held from May 2-5 in Chicago, IL.